The current misconception is that there are not enough U.S. labs to handle the demand for Covid-19 tests and results, but that’s simply not true.
The reality is that the large commercial labs that have current contracts with hospitals and health systems have been overwhelmed.
As a result, smaller companies/startups are stepping in to fill the void. One company is Boston-based biotech company Meenta, which is officially launching its Return to Work Covid-19 testing and surveillance program this week.
The program is based on Meenta’s online platform and provides access to many types of sample collection kits (viral and antibody tests) and has a capacity to perform 500,000 tests/weekly across more than 100 FDA/EUA certified clinical labs.
Meenta has a large proprietary, digitized network of FDA-approved labs and testing. Its business model was built on the premise of democratizing access to scientific equipment to give research scientists the ability to procure high priced life science equipment in an efficient way. Similar to an AirbnB model for research scientists.
By using its extraordinary network of labs, Meenta is uniquely positioned to help businesses seamlessly and consistently access these labs, thus eliminating recurring supply chain issues.
Meenta has the ability to conduct on-demand workplace testing and get results back in 24 to 48 hours –- rather than days/weeks. The company’s COVID-Tracker App and employer dashboard allows employers to safely control worksite re-entry, enable comprehensive symptom tracking and assessment, and quantify employee compliance. The 360-degree solution includes three critical pillars: a symptom assessment and tracker app, a data driven surveillance testing model, and onsite testing.
For more information, visit Meenta here.
